In a randomized, placebo-controlled, double-blind clinical trial, MASLD patients administered a 1 g hesperidin capsule for 12 weeks showed significant improvement in ALT, γ-glutamyltransferase, total cholesterol, triglyceride, high-sensitivity C-reactive protein, TNF-α, NF-κB, and hepatic steatosis compared with the placebo group [150]. Here, TNF is linked to Hepatic steatosis.